Secondary malignancy after imatinib therapy: Eight cases and review of the literature

Leukemia and Lymphoma

Volumn 53, Issue 9, 2012, Pages 1706-1708

  Duman, Berna Bozkurt ^a   Paydas, Semra ^a   Disel, Umut ^b   Besen, Ayberk ^b   Gurkan, Emel ^a  

^a CUKUROVA UNIVERSITY   (Turkey)

^b BASKENT UNIVERSITY   (Turkey)

Author keywords

CML; Imatinib; secondary malignancy; tyrosine kinase inhibitor

Indexed keywords

DASATINIB; HOMOHARRINGTONINE; HYDROXYUREA; IMATINIB; INTERFERON; NILOTINIB;

ADULT; AGED; CHRONIC MYELOID LEUKEMIA; CIGARETTE SMOKING; CLINICAL ARTICLE; COLON CANCER; DERMATOFIBROMA; DRUG RESISTANCE; HUMAN; LUNG CANCER; LYMPHOMA; PRIORITY JOURNAL; REVIEW; SECOND CANCER; SKIN CANCER; STOMACH CANCER; THYROID CANCER;

ADULT; AGED; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; YOUNG ADULT;

EID: 84865006789     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.666545     Document Type: Review

References (13)

1. íSánchez-Garca I, Gr ü tz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci USA 1995;92: 5287-5291.
2. R oszkiewicz F, Garidi R, Vaida I, et a l. Tyrosine kinase inhibitors and solid tumours: Case report and review of the literature. Pharmacology 2009;84:38-41.
3. B uchdunger E, Zimmermann J, Mett H, et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci USA 1995;92:2558-2562.
4. Paydas S, Duman BB, Ergin M. Non-Hodgkins lymphoma developing in a case with chronic myelocytic leukemia. Turk J Hematol 2011;28:232-234.
5. Heinrich MC, Griffi th DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-932.
6. Okuda K, Weisberg E, Gilliland DG, et a l. ARG tyrosine kinase activity is inhibited by STI571. Blood 2001;97:2440-2448.
7. S ummary of product characteristics of imatinib. 2007. Available from: H-406-PI-en.pdf
8. Roy L, Guilhot J, Martineau G, et al. Unexpected occurrence of second malignancies in patients treated with interferon followed by imatinib mesylate for chronic myelogenous leukemia. Leukemia 2005;19:1689-1692.
9. P iccin A, Conneally E, Lynch M, et a l. Adenomatoid tumor of the testis in a patient on imatinib therapy for chronic myeloid leukemia. Leuk Lymphoma 2006;47:1394-1396.
10. Tokuhara M, Gouda Y, Saito Y, et al. Gastrointestinal stromal tumor (GIST) that showed double new malignancies during imatinib therapy: A case report. J Clin Oncol 2008;26(Suppl.): Abstract 21517.
11. K alender ME, Sevinc A, Kucukdurmaz Z, et a l. Gastric and prostate adenocarcinoma in a patient with metastatic gastrointestinal stromal tumor. Onkologie 2007;30:568-570.
12. V erma D, Kantarjian H, Strom SS, et al. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) and other hematologic malignancies. Blood 2011;118:4353-4358.
13. Pilot PR, Sablinska K, Owen S, et al. Epidemiological analysis of second primary malignancies in more than 9500 patients treated with imatinib. Leukemia 2006;20:148; author reply 149.